Isoniazid resistance and the future of drug-resistant tuberculosis

被引:40
|
作者
Cohen, T
Becerra, MC
Murray, MB [1 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02115 USA
关键词
D O I
10.1089/mdr.2004.10.280
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Bacterial chromosomal mutations that confer antibiotic resistance often have deleterious effects that impose costs on reproductive fitness. This observation has led to the generalization that in the absence of the selection pressure exerted through treatment, the frequency of resistance will decrease. This model implies that the prudent use of antibiotics will eventually result in a decline in the prevalence of drug resistance. Recent work, however, suggests that some resistance-conferring mutations may not significantly impair fitness and that others may be accompanied by compensatory mutations that restore the organisms' reproductive potential. Thus drug resistance, once introduced, may persist unless specific measures are implemented to target prevalent drug-resistant cases. Here we present ecological evidence to support the hypothesis that mutations at the 315 position of katG confer isoniazid resistance for Mycobacterium tuberculosis without diminishing virulence or transmissibility.
引用
收藏
页码:280 / 285
页数:6
相关论文
共 50 条
  • [1] Reconsidering the Role of Isoniazid in Drug-Resistant Tuberculosis
    Davies, Geraint R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 210 (03) : 257 - 259
  • [2] Tetrandrine reverses drug resistance in isoniazid and ethambutol dual drug-resistant Mycobacterium tuberculosis clinical isolates
    Zhe Zhang
    Jie Yan
    Kaijin Xu
    Zhongkang Ji
    Lanjuan Li
    [J]. BMC Infectious Diseases, 15
  • [3] Tetrandrine reverses drug resistance in isoniazid and ethambutol dual drug-resistant Mycobacterium tuberculosis clinical isolates
    Zhang, Zhe
    Yan, Jie
    Xu, Kaijin
    Ji, Zhongkang
    Li, Lanjuan
    [J]. BMC INFECTIOUS DISEASES, 2015, 15
  • [4] Drug-resistant tuberculosis: Past, present, future
    Chiang, Chen-Yuan
    Centis, Rosella
    Migliori, Giovanni Battista
    [J]. RESPIROLOGY, 2010, 15 (03) : 413 - 432
  • [5] Extensively drug-resistant tuberculosis: back to the future
    Migliori, G. B.
    Sotgiu, G.
    Lange, C.
    Centis, R.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2010, 36 (03) : 475 - 477
  • [6] The future of molecular diagnostics for drug-resistant tuberculosis
    Heysell, Scott K.
    Houpt, Eric R.
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2012, 12 (04) : 395 - 405
  • [7] Resistance pattern in drug-resistant pulmonary tuberculosis
    Nagaraja, C.
    Shashibhushan, B. L.
    Sagar, C.
    Asif, M.
    Manjunath, P. H.
    [J]. JOURNAL OF POSTGRADUATE MEDICINE, 2011, 57 (03) : 181 - 183
  • [8] Rifampicin and Isoniazid minimum inhibitory concentrations in patients with drug-resistant tuberculosis
    Okonji, Osaretin Christabel
    Mugabo, Pierre
    [J]. ACTA CLINICA BELGICA, 2019, 74 : 42 - 43
  • [9] Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin
    Moulding, TS
    Le, HQ
    Rikleen, D
    Davidson, P
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2004, 8 (06) : 743 - 748
  • [10] DRUG-RESISTANT TUBERCULOSIS
    HANNA, BA
    BONK, S
    TICK, LK
    [J]. LANCET, 1993, 342 (8885): : 1496 - 1496